Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Enzon Pharmaceuticals, Inc. |
---|---|
Information provided by: | Enzon Pharmaceuticals, Inc. |
ClinicalTrials.gov Identifier: | NCT00520325 |
The goal of this clinical research study is to find the dose of EZN-2232 that can be given to MBL deficient pediatric cancer patients undergoing chemotherapy. The pharmacokinetics, pharmacodynamics, and safety of the study drug will also be studied.
Condition | Intervention | Phase |
---|---|---|
Cancer Hematologic Diseases Fever Neutropenia |
Drug: Intravenous recombinant human mannose binding lectin |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Dose Comparison, Parallel Assignment, Safety Study |
Official Title: | A Multi-Center Study of the Safety, Tolerability, Pharmacokinetics, and Dose Escalation of Intravenous Recombinant Human Mannose-Binding-Lectin (rhMBL) in MBL Deficient Pediatric Hematology/Oncology Patients With Fever and Neutropenia |
Estimated Enrollment: | 24 |
Study Start Date: | June 2007 |
Estimated Study Completion Date: | August 2009 |
Estimated Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
0.5 mg/kg |
Drug: Intravenous recombinant human mannose binding lectin
Intravenous(i.v.) administration for one dose. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
|
1.0 mg/kg |
Drug: Intravenous recombinant human mannose binding lectin
Intravenous(i.v.) administration for one dose. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
|
MBL deficient patients will be randomized in a ratio of 1:1 to receive a single dose of either 0.5 mg/kg or 1.0 mg/kg of intravenous rhMBL. A total of 24 patients will be treated in each of the rhMBL arms, (12 in the 0.5 mg/kg and 12 in the 1.0 mg/kg. All patients are to receive anti-infectious prophylactic supportive therapy as per institutional standards
Ages Eligible for Study: | 2 Years to 17 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria: Patients must meet all of the following criteria to be eligible for enrollment into the study:
Exclusion Criteria: Patients meeting any of the following exclusion criteria will not be eligible for enrollment.
AST or ALT >5 times upper limit of normal (ULN) OR Total bilirubin >2.5 times ULN.
United States, California | |
Children's Hospital Orange County | |
Orange, California, United States, 92686-3874 |
Principal Investigator: | Thomas Walsh, MD | NIH/National Cancer Institute |
Responsible Party: | Enzon Pharmaceuticals, Inc ( Nazish Huq ) |
Study ID Numbers: | EZN-2232-03, NCI # 07-C-0027 |
Study First Received: | August 23, 2007 |
Last Updated: | February 18, 2009 |
ClinicalTrials.gov Identifier: | NCT00520325 History of Changes |
Health Authority: | United States: Food and Drug Administration |
MBL deficient oncologic hematologic pediatric fever neutropenia |
Fever Signs and Symptoms Neutropenia Hematologic Diseases |
Agranulocytosis Leukocyte Disorders Leukopenia Granulocytopenia |
Fever Signs and Symptoms Neutropenia Hematologic Diseases |
Agranulocytosis Leukocyte Disorders Body Temperature Changes Leukopenia |